New Jersey, NJ, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Increasing awareness about reproductive and sexual health worldwide and increase in women population around the world are driving the growth of the market. The global hormonal contraceptive market is expected to grow from USD 19.31 Billion in 2017 to USD 31.07 Billion by 2025, at a CAGR of 5.80% during the forecast period 2018-2025, according to the new report published by Fior Markets.
Hormonal contraceptives are used as a birth control method. These pills act on the endocrine system. These are used to prevent ovulation and in turn pregnancy. However, they do not provide protection against HIV or other sexually transmitted infections. Two types of hormonal contraceptives are available in the market i.e. progestin-only contraceptive and combination hormonal contraceptive. Increasing focus towards family planning and need for preventing teenage pregnancies are fuelling the market. Hormonal contraceptives contain a small amount of man-made estrogen and progestin hormones.
Increasing women population globally and unwanted teenage pregnancies are boosting demand of hormonal contraceptives in forecast period. In addition, rising awareness about sexual health is also boosting the growth of the hormonal contraceptive market. Lack of awareness about these products in developing region may restrict the growth of the market. However, innovations in R&D activities, commercialization of new products and increasing adaptation of minimally invasive procedure or combined hormonal contraceptive are propelling the growth of the hormonal contraceptive market in forecast period.
DOWNLOAD FREE SAMPLE REPORT AT https://www.fiormarkets.com/report-detail/375980/request-sample
Key players operating in the global hormonal contraceptive market are Teva Pharmaceutical, Amgen, Sun Pharmaceutical, Bayer Healthcare, Piramal Healthcare, Cipla Limited, Pfizer, Inc., Glenmark Pharmaceuticals, Novartis AG, Lupin Pharmaceuticals, Reckitt Benckiser Plc, HLL Lifecare Limited, Boehringer Ingelheim GmbH, Watson Pharmaceuticals, Inc., V-Care Pharma Pvt. Ltd., Vardhman Life Care and others. In order to enhance their market position in the global hormonal contraceptive market, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership.
- Extensive product portfolio and expansion strategies by major players are contributing to the growth of the sector. For instance, in March 2017, TEVA launched generics of Minastrin 24 Fe-ethinyl estradiol & norethindrone acetate tablets and ferrous fumarate tablets. These are used as oral contraceptive in the U.S.
- For instance, in September 2016, Bayer Inc. launched Kyleena and expanded its IUD portfolio. It is a new Intrauterine System (IUS), to prevent pregnancy. This product will helps in preventing pregnancy for up to 5 years.
- In addition, in February 2017, Medicines 360 and Allergan partnered with health centers to address unintended pregnancies in areas impacted by Zika. This partnership helped in accessing a hormonal contraceptive Levonorgestrel-releasing Intrauterine System (LILETTA) . LILETTA prevents pregnancy for up to three years.
Oral contraceptive segment accounted for the largest market share of 38.94% in 2017
The method segment is classified into combined oral, oral contraceptive, implanted, injected, intrauterine, transdermal patch, and vaginal ring contraceptives. Oral contraceptive segment dominated the global hormonal contraceptive market and held the largest market share of 38.94% in 2017. Easy mode of administration, wide range of availability and high awareness about pills are driving the growth of the segment. The oral contraceptive are safe and reliable option for preventing unwanted pregnancy. It includes a combination of an estrogen and a progestogen.
Androgens is anticipated to dominate the global hormonal contraceptive market with highest CAGR of 6.58% over the forecast period.
Hormones segment is divided into androgens, estrogens, progestrogens, gonadotropins, antiandrogens and others. Androgens segment is anticipated to dominate the global hormonal contraceptive market with highest CAGR of 6.58% over the forecast period. Increase in prevalence of PCOS, fewer side effects and effective results than progestin contraceptives makes other hormones the preferred choice. Androgens are a group of hormones that play a role in male traits and reproductive activity. Androgens are produced primarily from the adrenal glands and the ovaries.
Browse full report with TOC at https://www.fiormarkets.com/report/global-hormonal-contraceptive-market-by-method-combined-oral-375980.html
Gynaecology centers segment is estimated to grow at a rapid growth rate over the forecast period
End-user segment is classified into hospitals, homecare, gynaecology centers, clinics and ambulatory surgical centers. Gynaecology centers segment is estimated to grow at a rapid growth rate over the forecast period. The gynaecology center provides a range of obstetrical and gynaecological services for women of all ages. These gynaecology centers are premier centers of excellence for women's health.
Regional Segment Analysis of the Hormonal Contraceptive Market
- North America (U.S. , Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of the Europe)
- Asia-Pacific (China, Japan India, Rest of APAC)
- South America (Brazil and Rest of South America)
- Middle East and Africa (UAE, South Africa, Rest of MEA)
North America region captured the largest share of global hormonal contraceptive market and was valued around USD 8.87 billion in 2017 whereas Asia pacific is expected to witness the highest CAGR of 6.48% in the forecast period. North America region is expected to dominate the market owing to high income, strong presence of major market players, higher awareness about sexual health and large number of unintended pregnancies. Asia pacific is projected to be the fastest growing region in the forecast period due to large fertile population and introduction of new female contraception devices.
About the report:
The global hormonal contraceptive market is analysed on the basis of value (USD Billion). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution and marketing channels analysis.
For Instant Purchase: https://www.fiormarkets.com/checkout.html?reportid=375980&type=single
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on sales@fiormarkets.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
About Fior Markets
Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients’ objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.
Contact Us
Avinash D
Head of Business Development
Phone: +1-201-465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com
To Know More Market Research Reports and Industry Analysis, Visit our Associate Website: www.marketresearchplace.com
Related Reports
- Global Surgical Imaging Market - https://www.fiormarkets.com/report/global-surgical-imaging-market-by-device-angiography-c-arms-375992.html
- Global Surgical Microscopes Market - https://www.fiormarkets.com/report/global-surgical-microscopes-market-by-type-on-casters-375993.html
- Global Transient Ischemic Attack Market - https://www.fiormarkets.com/report/global-transient-ischemic-attack-market-by-diagnosis-ct-375994.html
- Global Tumor Ablation Market - https://www.fiormarkets.com/report/global-tumor-ablation-market-by-technology-radiofrequency-microwave-375995.html